In recent years, the field of oncology has witnessed a remarkable transformation thanks to the groundbreaking innovation of antibody-drug conjugates (ADCs). These game-changing molecules have three key components: an antibody drug, a potent cytotoxic payload, and a specialized linker protein that binds them together. The result is a powerful therapeutic agent that can precisely target cancer cells, delivering its potent payload with surgical precision.
Currently, two ADCs have received approval for the treatment of DLBCL, namely Roche’s POLIVY and ADC Therapeutics’ ZYLNONTA. ZYLNONTA and POLIVY + bendamustine and rituximab (BR) are likely preferable DLBCL tre...
